Post-Op Radiation Ups Survival in Lung Cancer Patients
Posted on: Monday, 6 November 2006, 18:00 CST
Having radiation after lung cancer surgery appears to double some patients' survival odds, U.S. researchers said Monday.
In fact, a new study suggests that patients with lung cancer that has spread to mediastinal lymph nodes -- or those located between the chest, breastbone and spine -- who receive radiation therapy after surgery and chemotherapy live twice as long as patients who do not receive post-surgery radiation.
The study was part of a larger trial -- dubbed ANITA 1 -- which examined the effectiveness of chemotherapy after surgery in 840 patients with non-small cell lung cancer whose cancer had spread to the lymph nodes.
Those who underwent chemotherapy and radiation after surgery lived almost two years longer -- 47 versus 24 months -- than those patients who had chemotherapy alone.
This is the first time that a clinical trial has examined the effectiveness of radiation after surgery for lung cancer, said Jean-Yves Douillard, lead author of the study and a medical oncologist at the Centre Rene Gauducheau in St Herblain, France. The results show that radiation treatment should be considered for resected non-small cell lung cancer with involved mediastinal lymph nodes in addition to chemotherapy.
But he cautioned that the study needs to be confirmed in a prospective randomized trial of radiation, in addition to chemotherapy.
The results were prsented Monday at the American Society for Therapeutic Radiology and Oncology's 48th Annual Meeting in Philadelphia, Pa.
Source: United Press International
Related Articles
- First-of-its-Kind Collaboration Among Advocacy Groups Provides Lung Cancer Patients Personalized Information About Clinical Trials
- RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
- Calypso(R) Medical Technologies Reports Advancements in Radiation Treatment for Cancer Patients
- Enrollment of Breast and Ovarian Cancer Patients Commenced for Combination Therapy Trial to Include Generex Biotechnology's Novel Immunotherapeutic Vaccine
- Researchers Tapped Thomson Reuters Community of Cancer Patients for Studies To Be Reported at American Society of Clinical Oncology Conference
- First Prostate Cancer Patients Treated in a Phase I Clinical Trial As Part of a Collaboration Between Generex Biotechnology and the Saint Savas Cancer Hospital
- Generex Biotechnology Announces Treatment of First Breast Cancer Patients in Phase II Clinical Trial
- Machine Learning Could Speed Up Radiation Therapy for Cancer Patients
- Older Breast Cancer Patient Care Studied
- Radiation Helps Eye Cancer Patients Beat the Disease, Retain Vision
 |
 |
User Comments (0)
RSS Feeds